Your browser doesn't support javascript.
Should statins be considered for the management of mucormycosis in COVID-19?
Chatterjee, Subhankar; Vardhan, Bhagya; Singh, Deepa Kumari; Maitra, Abhishek; Ojha, Umesh Kumar.
  • Chatterjee S; Department of General Medicine, Patliputra Medical College & Hospital, Dhanbad, Jharkhand, India. Electronic address: chatterjeeaspiresubhankar.92@gmail.com.
  • Vardhan B; Patliputra Medical College & Hospital, Dhanbad, Jharkhand, India. Electronic address: sanket.5479@gmail.com.
  • Singh DK; Patliputra Medical College & Hospital, Dhanbad, Jharkhand, India. Electronic address: dr.deepapmch@gmail.com.
  • Maitra A; Patliputra Medical College & Hospital, Dhanbad, Jharkhand, India. Electronic address: abhi.maitra1995@gmail.com.
  • Ojha UK; Professor & Head,Department of General Medicine, Patliputra Medical College & Hospital, Dhanbad, Jharkhand, India. Electronic address: ukojha58@gmail.com.
Diabetes Metab Syndr ; 15(4): 102162, 2021.
Article in English | MEDLINE | ID: covidwho-1252680

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / COVID-19 / Hyperglycemia / Mucormycosis Topics: Long Covid Limits: Humans Country/Region as subject: Asia Language: English Journal: Diabetes Metab Syndr Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / COVID-19 / Hyperglycemia / Mucormycosis Topics: Long Covid Limits: Humans Country/Region as subject: Asia Language: English Journal: Diabetes Metab Syndr Year: 2021 Document Type: Article